New program offers ongoing allergy drug to previously treated patients
NCT ID NCT06631677
First seen May 14, 2026 · Last updated May 26, 2026 · Updated 2 times
Summary
This program provides continued access to dupilumab for adults with severe IgE-mediated food allergy who were previously treated with linvoseltamab and dupilumab in an earlier study. The goal is to keep offering the medication to eligible participants who completed the parent study. It is not a cure but aims to help manage the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.